methyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetate | 1061605-18-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetate
• 英文别名: Methyl 2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxyacetate；methyl 2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetate
• CAS: 1061605-18-2
• 化学式: C₁₆H₁₄N₂O₇
• 分子量: 346.296
• InChiKey: MGBMABBHWDSLMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  119
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetate 、 tert-butyl N-[10-[4-[[3-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]phenyl]carbamoyl]anilino]-10-oxodecyl]carbamate 在 三氟乙酸 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以51%的产率得到N-(3-((6-(1H-indol-3-yl)pyrimidin-4-yl)amino)phenyl)-4-(10-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)decanamido)benzamide
  参考文献：
  名称：

  [EN] SMALL MOLECULE DEGRADERS OF PHOSPHATIDYLINOSITOL-5-PHOSPHATE 4-KINASE TYPE 2 AND USES THEREOF
  [FR] AGENTS DE DÉGRADATION À PETITES MOLÉCULES DE PHOSPHATIDYLINOSITOL-5-PHOSPHATE 4-KINASE DE TYPE 2 ET LEURS UTILISATIONS

  摘要：

  本发明涉及双重功能化合物、组合物和方法，通过调节（例如，降低）PIP4K2A、PIP4K2B和PIP4K2C中至少一种的水平或活性来治疗疾病或病症。

  公开号：

  WO2022140554A1

文献信息

• 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
  申请人：CELGENE CORPORATION

  公开号：US20140073669A1

  公开（公告）日：2014-03-13

  Provided are 4′-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  提供了4'-O取代的异吲哚啉化合物及其药学上可接受的盐、溶剂化合物、笼合物、立体异构体和前药。公开了使用这些化合物的方法和制备药物组合物的方法。
• 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same
  申请人：Celgene Corporation

  公开号：US10385037B2

  公开（公告）日：2019-08-20

  Provided are 4′-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  本文提供了 4′-O 取代的异吲哚啉化合物及其药学上可接受的盐、溶解物、凝胶体、立体异构体和原药。还公开了这些化合物的使用方法和药物组合物。
• Methods to induce targeted protein degradation through bifunctional molecules
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10464925B2

  公开（公告）日：2019-11-05

  The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.

  本申请提供了作为蛋白质降解诱导分子的双功能化合物。本申请还涉及通过使用双官能化合物靶向降解内源性蛋白质的方法，该双官能化合物将脑龙结合分子与能够与靶向蛋白质结合的配体连接起来，可用于治疗增殖性疾病。本申请还提供了制造本申请化合物及其中间体的方法。
• METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
  申请人：Signal Pharmaceuticals, LLC

  公开号：US20140314752A1

  公开（公告）日：2014-10-23

  Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of an IMiD® immunomodulatory drug to a patient having a cancer.
• METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20180009779A1

  公开（公告）日：2018-01-11

  The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.